...will be huge! Have the analysts taken this into account, yet?
Sentiment: Strong Buy
Blank - as far as I am aware it's the Company's plan to approach both the FDA and EMEA with data from both the CF and NTM studies, and to negotiate labels in the US and Europe supported by the totality of the available data.
True... Who ever is approved first, will have off label sales....